Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248570 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
A Phase 2 study of Metastatic Prostate Cancer and Castration Resistant Prostatic Cancer, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03248570: Completed Phase 2 study of Metastatic Prostate Cancer and Castration Resistant Prostatic Cancer, sponsored by University of California, San Francisco.
NCT03248570 is a Phase 2 study of Metastatic Prostate Cancer and Castration Resistant Prostatic Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 26 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03248570, a Phase 2 study of Metastatic Prostate Cancer and Castration Resistant Prostatic Cancer, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
Primary Outcome
The rPFS rate is defined as the proportion of participants still alive at 6 months starting from the first day of study treatment with pembrolizumab. Participants will be censored on the date of documented tumor progression according to the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines or death due to any cause at 6 months. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment. The 6-month rPFS rate and the 95% confide
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Chemotherapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 2 |
What the finished NCT03248570 record still lists
NCT03248570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03248570 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03248570 about?
NCT03248570 is a clinical study titled "Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects". This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
What is the current status of trial NCT03248570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2018-02-20. Estimated completion is 2023-09-28.
What conditions does trial NCT03248570 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer, Castration Resistant Prostatic Cancer.
What interventions are being tested in trial NCT03248570?
The interventions under investigation include: Pembrolizumab (DRUG), Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03248570?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03248570 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03248570's enrollment target sits among peer trials
26 35th of 41 higher than 6 of 41 other Metastatic Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
-
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Study of Tarlatamab for People With Prostate Cancer
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI